Almirall Signs Up Forest For Once-Daily LABA
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest pays $75 million up front for U.S. rights to Almirall's once-daily long-acting beta agonist in combination with a corticosteroid.
You may also be interested in...
Germany’s IQWiG: New Year, Same Sternness On Dossier Structure
Pfizer’s kidney cancer drug Inlyta scrapes through the German added value assessment process but Almirall’s COPD product Eklira gets a “thumbs down,” showing that comparator selection is not the only deciding factor in the process.
BI's Spiriva HandiHaler Joins GSK's Advair Diskus In COPD Exacerbations Reduction Claim
The steroid-free, long-acting anticholinergic gains another selling point as others ready drugs for the $7 billion to $8 billion COPD market.
BI's Spiriva HandiHaler Joins GSK's Advair Diskus In COPD Exacerbations Reduction Claim
The steroid-free, long-acting anticholinergic gains another selling point as others ready drugs for the $7 billion to $8 billion COPD market.